The report provides industry landscape, competitive landscape and industry trends data on the immunochemistry industry . The report provides comprehensive data on the major industry developments affecting the industry, and key analytical content on the industry dynamics. The report also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.

Scope of the Research

- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
- Key sectors covered include disease specific immunochemistry, drugs of abuse/toxicology, therapeutic drug monitoring, endocrinology tests, immunochemistry analyzers, immunochemistry rapid tests, organ function assays and specific proteins.
- Annualized industry revenues data from 2003 to 2010, projection forward for 7 years to 2017. Firms share data for 2009.
- Qualitative analysis of key industry trends, industry drivers, and restraints by each category within immunochemistry industry .
- The report also covers data on the leading industry players, the competitive landscape, and the leading new product development and technologies.
- Key Companies covered include Roche, Siemens Healthcare and Abbott Laboratories.

Why Should You Get This Report?

- Develop business strategies by understanding the trends and developments that are driving the immunochemistry industry globally.
- Design and develop your product development, industry ing and sales strategies.
- Develop successful market-entry strategies .
- Identify key players best positioned to take advantage of the emerging industry opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- What’s the next big thing in the immunochemistry industry landscape? – Identify, understand and decide.
- Make more informed business decisions from the insightful and in-depth analysis of the global immunochemistry industry and the factors shaping it.

Table Of Contents

1 Table of contents

I Table of contents 3
I. 1 List of Data tables 6
I. 2 List of Charts 7

II Introduction and Overview 8
II. 1 GlobalData Report Guidance 8

III Immunochemistry Overview 9
III. 1 Disease Specific Immunochemistry 9
III. 1.1 Allergy Blood Tests 9
III. 1.2 Auto-immune Diseases 9
III. 1.3 Cardiac March kers 9
III. 1.4 Rheumatoid - Inflammatory Diseases March kers 9
III. 1.5 Tumor March kers 9
III. 2 Drugs of Abuse/Toxicology 10
III. 2.1 Drugs of Abuse 10
III. 2.2 Toxicology 10
III. 3 Therapeutic Drug Monitoring 10
III. 3.1 Antibiotic TDM/Antivirus TDM 10
III. 3.2 Cardiovascular TDM 10
III. 3.3 Central Nervous Systems TDM 10
III. 3.4 Immunosuppressant TDM 11
III. 4 Endocrinology Tests 11
III. 4.1 Fertility or Pregnancy Hormones 11
III. 4.2 Individual and Specified Hormones 11
III. 4.3 Thyroid Function Hormones 11
III. 5 Immunochemistry Analyzers 12
III. 5.1 Chemiluminescence Analyzers 12
III. 5.2 ELISA Instruments 12
III. 5.3 Immunofluorescence Analyzers 12
III. 5.4 Radioimmunoassay Analyzers 12
III. 6 Immunochemistry Rapid Tests 12
III. 7 Organ Function Assays 12
III. 8 Specific Proteins 12

IV Immunochemistry: World March ket Characterization 13
IV. 1 Immunochemistry March ket, Global, Sales (USD Million), Historical data, 2003-2010 13
IV. 2 Immunochemistry March ket, Global, Sales (USD Million), Forecasted data, 2010-2017 14
IV. 3 Immunochemistry, March ket Dynamics 15
IV. 3.1 Trends 15
IV. 3.2 March ket Drivers 16
IV. 3.3 March ket Restraints 21

V Immunochemistry March ket: Segment Analysis 23
V. 1 Disease Specific Immunochemistry March ket, Global, Sales (USD Million), Historical data, 2003-2010 23
V. 2 Disease Specific Immunochemistry March ket, Global, Sales (USD Million), Forecasted data, 2010-2017 24
V. 3 Disease Specific Immunochemistry, March ket Dynamics 25
V. 3.1 March ket Drivers 25
V. 3.2 March ket Restraint: Bottlenecks in the Development of New Biomarkers Impeding the Development of Disease Specific Tests 25
V. 4 Drugs of Abuse/Toxicology March ket, Global, Sales (USD Million), Historical data, 2003-2010 26
V. 5 Drugs of Abuse/Toxicology March ket, Global, Sales (USD Million), Forecasted data, 2010-2017 27
V. 6 Drugs of Abuse/Toxicology, March ket Dynamics 28
V. 6.1 March ket Drivers 28
V. 6.2 March ket Restraint: Developments in Testing Not Able to Match the Pace at Which Illegal Drugs are Being Invented 29
V. 7 Therapeutic Drug Monitoring March ket, Global, Sales (USD Million), Historical data, 2003-2010 30
V. 8 Therapeutic Drug Monitoring March ket, Global, Sales (USD Million), Forecasted data, 2010-2017 31
V. 9 Therapeutic Drug Monitoring, March ket Dynamics 32
V. 9.1 March ket Driver: High Awareness among Physicians with Regard to Available Diagnostic Options 32
V. 9.2 March ket Restraint: Lack of Medical History Records of Individuals in Underdeveloped Countries adversely affecting use of Therapeutic Drug Monitoring 32
V. 10 Endocrinology Tests March ket, Global, Sales (USD Million), Historical data, from 2003 to 2010 33
V. 11 Endocrinology Tests March ket, Global, Sales (USD Million), Forecasted data, 2010 - 2017 34
V. 12 Endocrinology Tests, March ket Dynamics 35
V. 12.1 March ket Driver: Surge in Reported Infertility Cases to Boost Testing Procedures 35
V. 12.2 March ket Restraint: Lack of Outreach about Options in Non-White Communities 35
V. 13 Immunochemistry Analyzers March ket, Global, Sales (USD Million), Historical data, 2003-2010 36
V. 14 Immunochemistry Analyzers March ket, Global, Sales (USD Million), Forecasted data, 2010-2017 37
V. 15 Immunochemistry Analyzers, March ket Dynamics 38
V. 15.1 March ket Driver: Accuracy offered by Analyzers is leading to their Higher Adoption 38
V. 15.2 March ket Restraint: Competition from Rapid Tests 38
V. 16 Immunochemistry Rapid Tests March ket, Global, Sales (USD Million), Historical data, 2003-2010 39
V. 17 Immunochemistry Rapid Tests March ket, Global, Sales (USD Million), Forecasted data, 2010-2017 40
V. 18 Immunochemistry Rapid Tests, March ket Dynamics 41
V. 18.1 March ket Driver: High Demand from Emergency Departments for Faster Testing Results 41
V. 18.2 March ket Restraint: Diagnostic Laboratories not in Favor of Rapid Tests Usage 41
V. 19 Organ Function Assays March ket, Global, Sales (USD Million), Historical data, 2003-2010 42
V. 20 Organ Function Assays March ket, Global, Sales (USD Million), Forecasted data, 2010-2017 43
V. 21 Organ Function Assays, March ket Dynamics 44
V. 21.1 March ket Driver: Increasing Incidences of Liver and Kidney Diseases and Availability of Numerous Testing Options to Boost March ket Growth 44
V. 21.2 March ket Restraint: High Cost Associated with the Overall Testing Discouraging People from Undergoing Tests 44
V. 22 Specific Proteins March ket, Global, Sales (USD Million), Historical data, 2003-2010 45
V. 23 Specific Proteins March ket, Global, Sales (USD Million), Forecasted data, 2010-2017 46
V. 24 Specific Proteins, March ket Dynamics 47
V. 24.1 March ket Driver: Use of Specific Protein Tests as the First Step in Diagnostics Boosting their Demand 47
V. 24.2 March ket Restraint: Lack of Knowledge about Proteins that are Specific to Each Disorder Affecting Development of Tests 47
6 World Immunochemistry March ket, by Country, Sales (USD Million), 2003-2017 48
VI. 1 Immunochemistry March ket, the US, Sales (USD Million), Historical data, 2003-2010 48
VI. 2 Immunochemistry March ket, the US, Sales (USD Million), Forecasted data, 2010-2017 49
VI. 3 Immunochemistry March ket, Canada, Sales (USD Million), Historical data, 2003 -2010 50
VI. 4 Immunochemistry March ket, Canada, Sales (USD Million), Forecasted data, 2010-2017 51
VI. 5 Immunochemistry March ket, the UK, Sales (USD Million), Historical data, 2003-2010 52
VI. 6 Immunochemistry March ket, the UK, Sales (USD Million), Forecasted data, 2010-2017 53
VI. 7 Immunochemistry March ket, Germany, Sales (USD Million), Historical data, 2003-2010 54
VI. 8 Immunochemistry March ket, Germany, Sales (USD Million), Forecasted data, 2010-2017 55
VI. 9 Immunochemistry March ket, France, Sales (USD Million), Historical data, 2003-2010 56
VI. 10 Immunochemistry March ket, France, Sales (USD Million), Forecasted data, 2010-2017 57
VI. 11 Immunochemistry March ket, Italy, Sales (USD Million), Historical data, 2003-2010 58
VI. 12 Immunochemistry March ket, Italy, Sales (USD Million), Forecasted data, 2010-2017 59
VI. 13 Immunochemistry March ket, Spain, Sales (USD Million), Historical data, 2003-2010 60
VI. 14 Immunochemistry March ket, Spain, Sales (USD Million), Forecasted data, 2010-2017 61
VI. 15 Immunochemistry March ket, Japan, Sales (USD Million), Historical data, 2003-2010 62
VI. 16 Immunochemistry March ket, Japan, Sales (USD Million), Forecasted data, 2010-2017 63
VI. 17 Immunochemistry March ket, China, Sales (USD Million), Historical data, 2003-2010 64
VI. 18 Immunochemistry March ket, China, Sales (USD Million), Forecasted data, 2010-2017 65
VI. 19 Immunochemistry March ket, India, Sales (USD Million), Historical data, 2003-2010 66
VI. 20 Immunochemistry March ket, India, Sales (USD Million), Forecasted data, 2010-2017 67
VI. 21 Immunochemistry March ket, Australia, Sales (USD Million), Historical data, 2003-2010 68
VI. 22 Immunochemistry March ket, Australia, Sales (USD Million), Forecasted data, 2010-2017 69
VI. 23 Immunochemistry March ket, Brazil, Sales (USD Million), Historical data, 2003-2010 70
VI. 24 Immunochemistry March ket, Brazil, Sales (USD Million), Forecasted data, 2010-2017 71
7 World Immunochemistry March ket: Strategic Competitive Assessment 72
VII. 1 Immunochemistry: Key March ket Participants 73
VII. 1.1 F. Hoffmann-La Roche Ltd. 73
VII. 1.2 Siemens Healthcare 77
VII. 1.3 Abbott Laboratories 81
VII. 1.4 Alere Inc. 85
8 World Immunochemistry March ket: Product Pipeline Assessment 88
VIII. 1 Profiles of Promising Immunochemistry Products under Clinical Development 88
VIII. 1.1 PROGENSA PCA3 Assay 88
VIII. 1.2 CertNDx Bladder Cancer Assay 90
VIII. 1.3 ADVIA Centaur CP System - UE3 Assay 92
VIII. 1.4 Access BPHA Assay 92
VIII. 1.5 Dimension Vista 1500 Intelligent Lab System CA 15-3 Assay 93
VIII. 1.6 Next Generation FIT for Colorectal Cancer 93
VIII. 1.7 RealTime mS9 Colorectal Cancer Test 93
VIII. 1.8 TheraScreen K-RAS Mutation Test 94
VIII. 1.9 AMIPredict 94
9 World Immunochemistry March ket: Strategic Deals Analysis 95
IX. 1 Key Acquisitions 95
IX. 1.1 Merck Completes the Acquisition of Millipore 95
IX. 1.2 Agilent Technologies Completes Acquisition of Varian 95
IX. 1.3 Inverness Medical Innovations (Alere Inc.) Takes Over 78.13% Stake in Standard Diagnostics 96
IX. 1.4 Thermo Fisher Scientific Completes Acquisition of B.R.A.H.M.S. 96
IX. 2 Key Partnership 97
IX. 2.1 Abbott Laboratories Enters Into an Agreement with GlaxoSmithKline 97

X Appendix 98
X. 1 Definitions 99
X. 1.1 Immunochemistry 99
X. 2 Acronyms 102
X. 3 Sources 104
X. 4 Research Methodology 104
X. 5 Primary Research 105
X. 6 Models 105
X. 7 Forecasted data s 105
X. 8 Expert Panels 106
X. 9 GlobalData Consulting 106
X. 10 Contact Us 106
X. 11 Disclaimer 106

1.1 List of Data tables
Data table 1: Immunochemistry March ket, Global, Sales (USD Million), 2003-2010 13
Data table 2: Immunochemistry March ket, Global, Sales (USD Million), 2010-2017 14
Data table 3: Laboratory Acquisitions, the US, 2002-2008 17
Data table 4: Immunochemistry March ket, Global, PE/VC Investments, Volume, from 2008 to 2010 19
Data table 5: Disease Specific Immunochemistry March ket, Global, Sales (USD Million), 2003-2010 23
Data table 6: Disease Specific Immunochemistry March ket, Global, Sales (USD Million), 2010-2017 24
Data table 7: Drugs of Abuse/Toxicology March ket, Global, Sales (USD Million), 2003-2010 26
Data table 8: Drugs of Abuse/Toxicology March ket, Global, Sales (USD Million), 2010-2017 27
Data table 9: Therapeutic Drug Monitoring March ket, Global, Sales (USD Million), 2003-2010 30
Data table 10: Therapeutic Drug Monitoring March ket, Global, Sales (USD Million), 2010-2017 31
Data table 11: Endocrinology Tests March ket, Global, Sales (USD Million), 2003-2010 33
Data table 12: Endocrinology Tests March ket, Global, Sales (USD Million), 2010-2017 34
Data table 13: Immunochemistry Analyzers March ket, Global, Sales (USD Million), 2003-2010 36
Data table 14: Immunochemistry Analyzers March ket, Global, Sales (USD Million), 2010-2017 37
Data table 15: Immunochemistry Rapid Tests March ket, Global, Sales (USD Million), 2003-2010 39
Data table 16: Immunochemistry Rapid Tests March ket, Global, Sales (USD Million), 2010-2017 40
Data table 17: Organ Function Assays March ket, Global, Sales (USD Million), 2003-2010 42
Data table 18: Organ Function Assays March ket, Global, Sales (USD Million), 2010-2017 43
Data table 19: Specific Proteins March ket, Global, Sales (USD Million), 2003-2010 45
Data table 20: Specific Proteins March ket, Global, Sales (USD Million), 2010-2017 46
Data table 21: Immunochemistry March ket, the US, Sales (USD Million), 2003-2010 48
Data table 22: Immunochemistry March ket, the US, Sales (USD Million), 2010-2017 49
Data table 23: Immunochemistry March ket, Canada, Sales (USD Million), 2003-2010 50
Data table 24: Immunochemistry March ket, Canada, Sales (USD Million), 2010-2017 51
Data table 25: Immunochemistry March ket, the UK, Sales (USD Million), 2003-2010 52
Data table 26: Immunochemistry March ket, the UK, Sales (USD Million), 2010-2017 53
Data table 27: Immunochemistry March ket, Germany, Sales (USD Million), 2003-2010 54
Data table 28: Immunochemistry March ket, Germany, Sales (USD Million), 2010-2017 55
Data table 29: Immunochemistry March ket, France, Sales (USD Million), 2003-2010 56
Data table 30: Immunochemistry March ket, France, Sales (USD Million), 2010-2017 57
Data table 31: Immunochemistry March ket, Italy, Sales (USD Million), 2003-2010 58
Data table 32: Immunochemistry March ket, Italy, Sales (USD Million), 2010-2017 59
Data table 33: Immunochemistry March ket, Spain, Sales (USD Million), 2003-2010 60
Data table 34: Immunochemistry March ket, Spain, Sales (USD Million), 2010-2017 61
Data table 35: Immunochemistry March ket, Japan, Sales (USD Million), 2003 - 2010 62
Data table 36: Immunochemistry March ket, Japan, Sales (USD Million), 2010-2017 63
Data table 37: Immunochemistry March ket, China, Sales (USD Million), 2003-2010 64
Data table 38: Immunochemistry March ket, China, Sales (USD Million), 2010-2017 65
Data table 39: Immunochemistry March ket, India, Sales (USD Million), 2003-2010 66
Data table 40: Immunochemistry March ket, India, Sales (USD Million), 2010-2017 67
Data table 41: Immunochemistry March ket, Australia, Sales (USD Million), 2003-2010 68
Data table 42: Immunochemistry March ket, Australia, Sales (USD Million), 2010-2017 69
Data table 43: Immunochemistry March ket, Brazil, Sales (USD Million), 2003-2010 70
Data table 44: Immunochemistry March ket, Brazil, Sales (USD Million), 2010 - 2017 71
Data table 45: Immunochemistry March ket, Global, Market Shares s by Sales s (USD Million), 2009 72
Data table 46: Immunochemistry Portfolio, F. Hoffmann-La Roche Ltd., 2011 73
Data table 47: Immunochemistry Pipeline Portfolio, F. Hoffmann-La Roche Ltd., 2011 74
Data table 48: Immunochemistry Portfolio, Siemens Healthcare, 2011 77
Data table 49: Immunochemistry Pipeline Portfolio, Siemens Healthcare, 2011 78
Data table 50: Immunochemistry Portfolio, Abbott Laboratories, 2010 81
Data table 51: Immunochemistry Pipeline Portfolio, Abbott Laboratories, 2010 81
Data table 52: Immunochemistry Portfolio, Alere Inc., 2011 85
Data table 53: Immunochemistry Pipeline Portfolio, Alere Inc., 2011 85
Data table 54: PROGENSA PCA3 Assay, Product Status, 2011 88
Data table 55: PROGENSA PCA3 Assay - Molecular Urine Tests for Prostate Cancer 88
Data table 56: PROGENSA PCA3 Assay - Clinical Evaluation of the PROGENSA PCA3 Assay in Men With a Previous Negative Biopsy Result 89
Data table 57: CertNDx Bladder Cancer Assay, Product Status, 2011 90
Data table 58: CertNDx Bladder Cancer Assay - Phase III Study of Bladder Cancer Recurrence Surveillance 90
Data table 59: CertNDx Bladder Cancer Assay - A Study On ADAM 12 Cleaving Extracellular Matrix Proteins and Correlate With Cancer Status and Stage 91
Data table 60: ADVIA Centaur CP System - UE3 Assay, Product Status, 2011 92
Data table 61: Access BPHA Assay, Product Status, 2011 92
Data table 62: Dimension Vista 1500 Intelligent Lab System CA 15-3 Assay, Product Status, 2011 93
Data table 63: Next Generation FIT for Colorectal Cancer, Product Status, 2011 93
Data table 64: RealTime mS9 Colorectal Cancer Test, Product Status, 2011 93
Data table 65: TheraScreen K-RAS Mutation Test, Product Status, 2011 94
Data table 66: AMIPredict, Product Status, 2011 94

1.2 List of Charts

Chart 1: Immunochemistry March ket, Global, Sales (USD Million), 2003-2010 13
Chart 2: Immunochemistry March ket, Global, Sales (USD Million), 2010-2017 14
Chart 3: Laboratory Acquisitions, the US, 2002-2008 16
Chart 4: Immunochemistry March ket, Global, PE/VC Investments, Volume, from 2008 to 2010 19
Chart 5: Disease Specific Immunochemistry March ket, Global, Sales (USD Million), 2003-2010 23
Chart 6: Disease Specific Immunochemistry March ket, Global, Sales (USD Million), 2010-2017 24
Chart 7: Drugs of Abuse/Toxicology March ket, Global, Sales (USD Million), 2003-2010 26
Chart 8: Drugs of Abuse/Toxicology March ket, Global, Sales (USD Million), 2010-2017 27
Chart 9: Drug Tests, Olympics, 2000-2008 28
Chart 10: Therapeutic Drug Monitoring March ket, Global, Sales (USD Million), 2003-2010 30
Chart 11: Therapeutic Drug Monitoring March ket, Global, Sales (USD Million), 2010-2017 31
Chart 12: Endocrinology Tests March ket, Global, Sales (USD Million), 2003-2010 33
Chart 13: Endocrinology Tests March ket, Global, Sales (USD Million), 2010-2017 34
Chart 14: Immunochemistry Analyzers March ket, Global, Sales (USD Million), 2003-2010 36
Chart 15: Immunochemistry Analyzers March ket, Global, Sales (USD Million), 2010-2017 37
Chart 16: Immunochemistry Rapid Tests March ket, Global, Sales (USD Million), 2003-2010 39
Chart 17: Immunochemistry Rapid Tests March ket, Global, Sales (USD Million), 2010-2017 40
Chart 18: Organ Function Assays March ket, Global, Sales (USD Million), 2003-2010 42
Chart 19: Organ Function Assays March ket, Global, Sales (USD Million), 2010-2017 43
Chart 20: Specific Proteins March ket, Global, Sales (USD Million), 2003-2010 45
Chart 21: Specific Proteins March ket, Global, Sales (USD Million), 2010-2017 46
Chart 22: Immunochemistry March ket, the US, Sales (USD Million), 2003-2010 48
Chart 23: Immunochemistry March ket, the US, Sales (USD Million), 2010-2017 49
Chart 24: Immunochemistry March ket, Canada, Sales (USD Million), 2003-2010 50
Chart 25: Immunochemistry March ket, Canada, Sales (USD Million), 2010-2017 51
Chart 26: Immunochemistry March ket, the UK, Sales (USD Million), 2003-2010 52
Chart 27: Immunochemistry March ket, the UK, Sales (USD Million), 2010-2017 53
Chart 28: Immunochemistry March ket, Germany, Sales (USD Million), 2003-2010 54
Chart 29: Immunochemistry March ket, Germany, Sales (USD Million), 2010-2017 55
Chart 30: Immunochemistry March ket, France, Sales (USD Million), 2003-2010 56
Chart 31: Immunochemistry March ket, France, Sales (USD Million), 2010-2017 57
Chart 32: Immunochemistry March ket, Italy, Sales (USD Million), 2003-2010 58
Chart 33: Immunochemistry March ket, Italy, Sales (USD Million), 2010-2017 59
Chart 34: Immunochemistry March ket, Spain, Sales (USD Million), 2003-2010 60
Chart 35: Immunochemistry March ket, Spain, Sales (USD Million), 2010-2017 61
Chart 36: Immunochemistry March ket, Japan, Sales (USD Million), 2003 - 2010 62
Chart 37: Immunochemistry March ket, Japan, Sales (USD Million), 2010-2017 63
Chart 38: Immunochemistry March ket, China, Sales (USD Million), 2003-2010 64
Chart 39: Immunochemistry March ket, China, Sales (USD Million), 2010-2017 65
Chart 40: Immunochemistry March ket, India, Sales (USD Million), 2003-2010 66
Chart 41: Immunochemistry March ket, India, Sales (USD Million), 2010-2017 67
Chart 42: Immunochemistry March ket, Australia, Sales (USD Million), 2003-2010 68
Chart 43: Immunochemistry March ket, Australia, Sales (USD Million), 2010-2017 69
Chart 44: Immunochemistry March ket, Brazil, Sales (USD Million), 2003-2010 70
Chart 45: Immunochemistry March ket, Brazil, Sales (USD Million), 2010 - 2017 71
Chart 46: Immunochemistry March ket, Global, Market Shares s (%), 2009 72
Chart 47: F. Hoffmann-La Roche Ltd, SWOT 75
Chart 48: Siemens Healthcare, SWOT 79
Chart 49: Abbott Laboratories, SWOT 83
Chart 50: Alere Inc., SWOT 86F. Hoffmann-La Roche Ltd.
Siemens Healthcare
Abbott Laboratories
Alere Inc.

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Shadi

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers

New Frontiers in Automated Microbiology: Global Challenges, Emerging Technologies, Competitive Landscape

New Frontiers in Automated Microbiology: Global Challenges, Emerging Technologies, Competitive Landscape

  • $ 21 100
  • Industry report
  • May 2014
  • by Venture Planning Group

“New Frontiers in Automated Microbiology: Global Challenges, Emerging Technologies, Competitive Landscape” is Venture Planning Group's new seven-country strategic analysis of the major business opportunities ...

Emerging Opportunities in the Global Virology and Bacteriology Testing Market

Emerging Opportunities in the Global Virology and Bacteriology Testing Market

  • $ 21 100
  • Industry report
  • June 2014
  • by Venture Planning Group

“Emerging Opportunities in the Global Virology and Bacteriology Testing Market” is a new seven-country strategic analysis of major business opportunities emerging in the infectious disease testing ...

New Frontiers in Coagulation Testing: Global Challenges, Emerging Technologies, Competitive Landscape

New Frontiers in Coagulation Testing: Global Challenges, Emerging Technologies, Competitive Landscape

  • $ 21 100
  • Industry report
  • May 2014
  • by Venture Planning Group

“New Frontiers in Coagulation Testing: Global Challenges, Emerging Technologies, Competitive Landscape” is Venture Planning Group's new seven-country report designed to help current suppliers and potential ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.